David D McManus1, Honghuang Lin2, Kahraman Tanriverdi3, Michael Quercio4, Xiaoyan Yin5, Martin G Larson6, Patrick T Ellinor7, Daniel Levy8, Jane E Freedman3, Emelia J Benjamin9. 1. National Heart Lung and Blood Institute's and Boston University's Framingham Heart Study, Framingham, Massachusetts; Cardiology Division, Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts; Epidemiology Division, Department of Quantitative Health Sciences, University of Massachusetts Medical School Worcester, Massachusetts. Electronic address: mcmanusd@ummhc.org. 2. National Heart Lung and Blood Institute's and Boston University's Framingham Heart Study, Framingham, Massachusetts; Computational Biomedicine Section, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts. 3. National Heart Lung and Blood Institute's and Boston University's Framingham Heart Study, Framingham, Massachusetts; Cardiology Division, Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts. 4. Cardiology Division, Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts. 5. National Heart Lung and Blood Institute's and Boston University's Framingham Heart Study, Framingham, Massachusetts. 6. National Heart Lung and Blood Institute's and Boston University's Framingham Heart Study, Framingham, Massachusetts; Department of Mathematics and Statistics, Boston University, Boston, Massachusetts; Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts. 7. Cardiac Arrhythmia Service, Massachusetts General Hospital, Boston, Massachusetts; Cardiovascular Research Center, Massachusetts General Hospital, Charlestown, Massachusetts. 8. National Heart Lung and Blood Institute's and Boston University's Framingham Heart Study, Framingham, Massachusetts; Population Research Branch and Division of Intramural Research, National Heart, Lung, and Blood Institute of the National Institutes of Health, Bethesda, Massachusetts. 9. Section of Cardiovascular Medicine, Department of Medicine, Boston University, Boston, Massachusetts; Preventive Medicine Section, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts; Epidemiology Department, Boston University School of Public Health, Boston, Massachusetts.
Abstract
BACKGROUND: MicroRNA (miRNA) expression in atrial tissue has been implicated in pathologic susceptibility to atrial fibrillation (AF). Nevertheless, data on how circulating levels relate to AF are limited. OBJECTIVE: The purpose of this study was to test the hypothesis that circulating miRNAs are associated with AF. METHODS: Among 2445 Framingham Heart Study Offspring participants, we measured the expression of 385 circulating whole blood miRNAs by high-throughput quantitative reverse transcriptase polymerase chain reaction. We related miRNA levels with prevalent and new-onset AF. RESULTS: Mean age of the cohort was 66.3 ± 8.9 years, and 56% were women; 153 participants had clinically apparent AF at baseline, and 107 developed AF during median follow-up of 5.4 years. miRNA-328 (miR-328) expression was lower among participants with prevalent AF (8.76 cycle threshold) compared to individuals with no AF (7.75 cycle threshold, P <.001). The association between miR-328 and prevalent AF persisted after adjustment for age, sex, and technical covariates (odds ratio 1.21, P = 1.8 × 10(-4)) but was attenuated in analyses adjusting for clinical AF risk factors (odds ratio 1.14, P = .017). In contrast to the associations between miR-328 and prevalent AF, none of the circulating miRNAs were associated with incident AF. CONCLUSION: Circulating levels of miR-328, a miRNA known to promote atrial electrical remodeling by reducing L-type Ca(2+) channel density, were associated with prevalent AF. Adjustment for risk factors that promote atrial remodeling, including hypertension, attenuated the association between miR-328 and AF, potentially implicating miR-328 as a potential mediator of atrial remodeling and AF vulnerability.
BACKGROUND: MicroRNA (miRNA) expression in atrial tissue has been implicated in pathologic susceptibility to atrial fibrillation (AF). Nevertheless, data on how circulating levels relate to AF are limited. OBJECTIVE: The purpose of this study was to test the hypothesis that circulating miRNAs are associated with AF. METHODS: Among 2445 Framingham Heart Study Offspring participants, we measured the expression of 385 circulating whole blood miRNAs by high-throughput quantitative reverse transcriptase polymerase chain reaction. We related miRNA levels with prevalent and new-onset AF. RESULTS: Mean age of the cohort was 66.3 ± 8.9 years, and 56% were women; 153 participants had clinically apparent AF at baseline, and 107 developed AF during median follow-up of 5.4 years. miRNA-328 (miR-328) expression was lower among participants with prevalent AF (8.76 cycle threshold) compared to individuals with no AF (7.75 cycle threshold, P <.001). The association between miR-328 and prevalent AF persisted after adjustment for age, sex, and technical covariates (odds ratio 1.21, P = 1.8 × 10(-4)) but was attenuated in analyses adjusting for clinical AF risk factors (odds ratio 1.14, P = .017). In contrast to the associations between miR-328 and prevalent AF, none of the circulating miRNAs were associated with incident AF. CONCLUSION: Circulating levels of miR-328, a miRNA known to promote atrial electrical remodeling by reducing L-type Ca(2+) channel density, were associated with prevalent AF. Adjustment for risk factors that promote atrial remodeling, including hypertension, attenuated the association between miR-328 and AF, potentially implicating miR-328 as a potential mediator of atrial remodeling and AF vulnerability.
Authors: Yoko Miyasaka; Marion E Barnes; Bernard J Gersh; Stephen S Cha; Kent R Bailey; Walter P Abhayaratna; James B Seward; Teresa S M Tsang Journal: Circulation Date: 2006-07-03 Impact factor: 29.690
Authors: Karin S Coyne; Clark Paramore; Susan Grandy; Marco Mercader; Matthew Reynolds; Peter Zimetbaum Journal: Value Health Date: 2006 Sep-Oct Impact factor: 5.725
Authors: Eva van Rooij; Lillian B Sutherland; Ning Liu; Andrew H Williams; John McAnally; Robert D Gerard; James A Richardson; Eric N Olson Journal: Proc Natl Acad Sci U S A Date: 2006-11-15 Impact factor: 11.205
Authors: Hetty C de Boer; Coen van Solingen; Jurriën Prins; Jacques M G J Duijs; Menno V Huisman; Ton J Rabelink; Anton Jan van Zonneveld Journal: Eur Heart J Date: 2013-02-04 Impact factor: 29.983
Authors: Eva van Rooij; Lillian B Sutherland; Jeffrey E Thatcher; J Michael DiMaio; R Haris Naseem; William S Marshall; Joseph A Hill; Eric N Olson Journal: Proc Natl Acad Sci U S A Date: 2008-08-22 Impact factor: 11.205
Authors: Karen L Novik; John J Spinelli; Amy C Macarthur; Karey Shumansky; Payal Sipahimalani; Stephen Leach; Agnes Lai; Joseph M Connors; Randy D Gascoyne; Richard P Gallagher; Angela R Brooks-Wilson Journal: Cancer Epidemiol Biomarkers Prev Date: 2007-06 Impact factor: 4.254
Authors: David D McManus; Kahraman Tanriverdi; Honghuang Lin; Nada Esa; Menhel Kinno; Divakar Mandapati; Stanley Tam; Okike N Okike; Patrick T Ellinor; John F Keaney; J Kevin Donahue; Emelia J Benjamin; Jane E Freedman Journal: Heart Rhythm Date: 2014-10-09 Impact factor: 6.343
Authors: Mohit K Turagam; Mahek Mirza; Paul H Werner; Jasbir Sra; David C Kress; A Jamil Tajik; Arshad Jahangir Journal: Cardiol Rev Date: 2016 Mar-Apr Impact factor: 2.644
Authors: Kathleen T Nevola; Douglas P Kiel; Andrew R Zullo; Stefan Weiss; Georg Homuth; Ines Foessl; Barbara Obermayer-Pietsch; Katherine J Motyl; Christine W Lary Journal: J Bone Miner Res Date: 2020-09-22 Impact factor: 6.741